Stock Events

Stock Events

Verastem 

$8.20
93
+$0.22+2.76% Friday 20:00
+$0.05+0.61%Friday 23:56After hours

Statistics

Day High
8.21
Day Low
8.18
52W High
11.25
52W Low
3.43
Volume
82,696
Avg. Volume
-
Mkt Cap
742.62M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

11NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-1.35
-1.02
-0.68
-0.35
Expected EPS
-0.44
Actual EPS
N/A

Financials

-677.59%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
30.91MRevenue
-209.47MNet Income

Analyst Ratings

13.83Average Price Target
The highest estimate is 18.00.
From 6 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow VSTM. It's not an investment recommendation.
Microsoft
14
MSFT
NVIDIA
13
NVDA
Realty Income
12
O
Apple
11
AAPL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Incyte
INCY
Mkt Cap25.21B
Incyte Corporation focuses on the discovery, development, and commercialization of various therapeutics, including those in oncology, which directly competes with Verastem's cancer-focused pipeline.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol-Myers Squibb operates in the biopharmaceutical industry, developing drugs for cancer which puts it in direct competition with Verastem's oncology segment.
AMGEN
AMGN
Mkt Cap233.78B
Amgen is a biotech company with a strong focus on cancer and oncology treatments, competing in the same space as Verastem.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences is involved in the research and development of therapeutic products in the oncology sector, making it a competitor to Verastem.
Merck
MRK
Mkt Cap366B
Merck & Co., Inc. is a global healthcare company that produces cancer treatments, competing with Verastem in the oncology market.
Pfizer
PFE
Mkt Cap159.36B
Pfizer Inc. has a broad portfolio of oncology drugs, directly competing with Verastem in the cancer treatment space.
Novartis
NVS
Mkt Cap292.35B
Novartis AG engages in the research, development, and marketing of healthcare products, including oncology, which competes with Verastem's focus.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie Inc. focuses on pharmaceuticals including cancer treatments, positioning it as a competitor to Verastem.
Lilly(Eli) &
LLY
Mkt Cap1.05T
Eli Lilly and Company is a global healthcare leader that works on developing oncology drugs, making it a competitor to Verastem.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca PLC is a biopharmaceutical company focusing on the discovery and development of products for various disease areas including cancer, competing with Verastem.

About

Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
Show more...
CEO
Daniel W. Paterson
Employees
102
Country
United States
ISIN
US92337C2035
WKN
000A3EHM3

Listings

STU
DE
2VSA.STU
BOATS
BOATS
VSTM.BOATS
F
DE
2VSA.F
MU
DE
2VSA.MU

0 Comments

Share your thoughts

FAQ

What is Verastem stock price today?▼
The current price of VSTM is $8.20 USD — it has increased by +2.76% in the past 24 hours. Watch Verastem stock price performance more closely on the chart.
What is Verastem stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Verastem stocks are traded under the ticker VSTM.
Is Verastem stock price growing?▼
VSTM stock has risen by +13.57% compared to the previous week, the month change is a +39.69% rise, over the last year Verastem has showed a -23.86% decrease.
What is Verastem market cap?▼
Today Verastem has the market capitalization of 742.62M
When is the next Verastem earnings date?▼
Verastem is going to release the next earnings report on November 11, 2026.
What were Verastem earnings last quarter?▼
VSTM earnings for the last quarter are -0.35 USD per share, whereas the estimation was -0.43 USD resulting in a +18.7% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Verastem revenue for the last year?▼
Verastem revenue for the last year amounts to 30.91M USD.
What is Verastem net income for the last year?▼
VSTM net income for the last year is -209.47M USD.
How many employees does Verastem have?▼
As of September 05, 2026, the company has 102 employees.
In which sector is Verastem located?▼
Verastem operates in the Health & Wellness sector.
When did Verastem complete a stock split?▼
The last stock split for Verastem was on June 01, 2023 with a ratio of 1:12.
Where is Verastem headquartered?▼
Verastem is headquartered in NEEDHAM, United States.